Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs ...
Panelists discuss how dermatologic toxicities from EGFR-targeted therapies can be effectively managed through a comprehensive approach combining prophylactic measures, early interventions with oral ...
"When most people hear the words palliative care, they immediately think about hospice or end-of-life care. This includes ...
Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to ...
Here are the top 5 articles from 2024 reported on Oncology Nursing News. Opinion: The Media May Have Oversold AOH1996, City ...
The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...
Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel
Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's ...
Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's ...
Treatment sequencing with targeted therapies may help to improve overall survival, according to real-world data.
Medical experts discuss strategies for patient education on managing potential adverse events of lorlatinib and other ALK ...
Panelists discuss how amivantamab’s dual targeting of EGFR and MET may address resistance mechanisms and unmet needs in ...
Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback